Life
Science

Physics & Engineering

 

Sortieren nach: Datum | Licensing Manager
Home › Technology Offers
Es wurden 2 Technologieangebote gefunden

Chemerin9 Variants for Diagnosis and Therapy of Pancreatic and Oesophageal Cancer


07.03.2012 | Ref.Nr. 11115
Download as PDF PDF Download Share
Life Science › Medical Devices › Imaging

Imaging of subcutaneous oesophageal tumors at the flanks of the animals with labeled vChem9 peptide (source: Grötzinger, Bandholz, NP2D 2011).Background
Pancreatic and oesophageal tumors are comparatively rare but characterized by high mortality rates. One reason is that such tumors are commonly detected only at advanced stages of cancerous disease. Often the disease is detected by chance, for instance during the course of other medical examinations.

Technology
Occurrence of CMKLR1, a G protein-coupled receptor, was found to be elevated in oesophageal squamous cell carcinoma and pancreatic adenocarcinoma. We offer peptidic variants of CMKLR1 ligand Chemerin9 with highest stability and optimized ligand binding properties. Attached to a detectable label or therapeutically active agent the peptide variants are suitable for imaging of mestastases formation in pancreatic and oesophageal tumors and its therapy in a theranostic approach.
 

IP Rights
European priority application filed

Patent Owner
Charité – Universitätsmedizin Berlin

Application Area:
Predictive imaging, Therapy monitoring, Micro-dosing approach
Development Stage: in vivo
Schlagworte: Imaging, micro dosing delivery, theranostics, tumor therapy,
Weitere Kategorien: Diagnostics, Life Science, Medical Devices, Imaging
Bild des Benutzers Dr. Janin Hofmann
Licensing Manager: Dr. Janin Hofmann
T +49 30 2125 4828
F +49 30 2125 4822
janin.hofmann@ipal.de
Suitable Industry: Diagnostics, Biotechnology, Pharmaceuticals
Benefits:
  • Reliable diagnosis of primary pancreatic and oesophageal tumors
  • Promising Target: CMKLR1
  • Reliable detection of early metastases
  • Suitable for routine medical screening

New Methods for Elastography of the Liver, Heart and Brain


20.10.2009 | Ref.Nr. 06023
Download as PDF PDF Download Share
Life Science › Medical Devices › Imaging

The new methods are based on magnetic resonance imaging (MRI), magnetic resonance elastography (MRE), and ultrasonography (US). The main goal of the inventions is to diagnose cardiac dysfunction by non-invasive elasticity measurements using either MRI or US. Additionally, the innovative methods considerably improve MRE of liver fibrosis and potentially allow an elasticity-based diagnosis of neurodegenerative diseases.

The new methods are based on three crucial developments:
  • Rigid transmission of shear waves into the body. This allows robust mechanical stimulation of liver, heart and brain by arbitrary waveforms using relatively high wave amplitudes without destructive interferences and discomfort to the patient.  (MRI and US)
  • Accelerated magnetic encoding of slow tissue vibrations (fractional MRE). This for the first time allows the acquisition of externally induced oscillations by MRI during cardiac motion. (MRI)
  • Assessment of cardiac function using modulated shear waves. This is a simple and unique way to measure intraventricular pressure changes without the need for invasive catheter examinations. (MRI and US)

IP Rights
06023    EP Application, Publ. No. EP2007281  (A1).
06023    DE Application, Publ. No. DE102006037160  (A1).
06024    DE Application, Publ. No. DE102006062763  (A1).
06023    US Application No. 12/297,133.
07023    German Patent Application DE 102007022469 filed on May 8, 2007.
07023    PCT Application PCT/EP 2008/055617 filed on May 7, 2008.

Origin
Charité Berlin

Application Area:
Medical
Development Stage: Concept
Type of Collaboration: License, Sale, Collaboration
Schlagworte: Body, Cardiac Dysfunction, Diagnose, Magnetic Resonance Elastography, Magnetic Resonance Imaging, MRE, MRI, Ultrasonography, US,
Weitere Kategorien: Life Science, Medical Devices, Imaging
Bild des Benutzers Dr. Kirk Haselton
Licensing Manager: Dr. Kirk Haselton
T +49 30 2125 4842
F +49 30 2125 4822
kirk.haselton@ipal.de
Market Potential: Worldwide
Benefits:

The techniques can be combined for the diagnosis of heart failure or to acquire ventricular pressure data without catheter intervention. In other applications rigid wave transmission can be combined with fractional MRE to improve the accuracy and significance of liver MRE, thereby avoiding harmful and expensive biopsies.